Reaction

Prostatic Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,458 reports · 78 co-occurring drugs

As of the last recalculation, Prostatic Disorder appears in 5,458 FAERS reports alongside 78 co-occurring drug terms. The strongest observed disproportionality signal is RANITIDINE (PRR 18.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranitidine	837	18.8	18.9
Testosterone Cypionate	38	16.3	16.4
Ranitidine Hydrochloride	157	11.3	11.3
Finasteride	160	10.4	10.4
Tamsulosin Hydrochloride	51	9.6	9.6
Terazosin Hydrochloride	22	9.5	9.5
Doxazosin Mesylate	54	5.8	5.8
Fesoterodine Fumarate	14	4.9	4.9
Doxazosin	36	4.9	4.9
Sildenafil Citrate	142	4.3	4.3
Ezetimibe And Simvastatin	17	4.3	4.3
Testosterone	25	4.1	4.1
Tafamidis	12	3.9	3.9
Amlodipine Besylate And Valsartan	11	3.8	3.8
Prasugrel Hydrochloride	10	3.8	3.8
Diphenoxylate Hydrochloride And Atropine Sulfate	13	3.6	3.6
Ibrutinib	75	3.6	3.6
Psyllium Husk	9	3.5	3.5
Octreotide Acetate	27	3.4	3.4
Acalabrutinib	10	3.2	3.2
Nitrofurantoin	13	3.0	3.0
Nitrofurantoin (Monohydrate/Macrocrystals)	13	3.0	3.0
Gemfibrozil	11	2.8	2.8
Infliximab-Dyyb	21	2.7	2.7
Dofetilide	7	2.5	2.5
Valsartan And Hydrochlorothiazide	9	2.5	2.5
Mirabegron	24	2.4	2.4
Budesonide And Formoterol Fumarate Dihydrate	57	2.3	2.3
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	2.2	2.2
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	2.2	2.2
Ranolazine	6	2.2	2.2
Budesonide, Glycopyrrolate, And Formoterol Fumarate	6	2.2	2.2
Bosutinib	5	2.1	2.1
Methadone Hydrochloride	6	2.1	2.1
Sacubitril And Valsartan	64	2.1	2.1
Losartan	96	2.1	2.1
Glipizide	33	2.1	2.1
Tiotropium Bromide Inhalation Spray	6	2.0	2.0
Rivastigmine	10	2.0	2.0
Latanoprost	26	2.0	2.0
Avapritinib	6	1.9	1.9
Umeclidinium Bromide And Vilanterol Trifenatate	8	1.8	1.8
Nintedanib	15	1.8	1.8
Tiotropium Bromide	65	1.8	1.8
Relugolix	11	1.8	1.8
Suvorexant	6	1.8	1.8
Atomoxetine Hydrochloride	11	1.8	1.8
Travoprost	4	1.8	1.8
Ticagrelor	14	1.7	1.7
Lenalidomide	180	1.6	1.6
Ruxolitinib	30	1.6	1.6
Risankizumab-Rzaa	34	1.6	1.6
Fexofenadine Hydrochloride	9	1.6	1.6
Dapagliflozin	13	1.6	1.6
Sodium Oxybate	27	1.6	1.6
Alirocumab	10	1.5	1.5
Leuprolide Acetate	30	1.5	1.5
Loratadine And Pseudoephedrine Sulfate	3	1.4	1.4
Vibegron	3	1.4	1.4
Faricimab	3	1.4	1.4
Glecaprevir And Pibrentasvir	4	1.4	1.4
Siponimod	3	1.3	1.3
Pomalidomide	34	1.3	1.3
Venetoclax	19	1.2	1.2
Canagliflozin	9	1.1	1.1
Dasatinib	11	1.1	1.1
Abiraterone	4	1.1	1.1
Cabozantinib	14	1.1	1.1
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	12	1.1	1.1
Pimavanserin Tartrate	15	1.0	1.0
Abiraterone Acetate	10	0.9	0.9
Enzalutamide	14	0.9	0.9
Pirfenidone	9	0.8	0.8
Somatropin	14	0.7	0.7
Valbenazine	4	0.6	0.6
Nirmatrelvir And Ritonavir	8	0.6	0.6
Evolocumab	23	0.5	0.5
Apremilast	19	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.